Le Lézard
Classified in: Health, Business
Subjects: PDT, OTC

Marapharm Ventures Inc. Announces That the First Plants Are Being Grown in the Las Vegas, Nevada Facility


KELOWNA, British Columbia, September 18, 2017 /PRNewswire/ --

Marapharm Ventures Inc. ("Marapharm" or the "Company") (CSE: MDM.CN) (FSE: 2M0) (OTCQB: MRPHF) is growing plants at it's facility in Las Vegas. The seeds have "popped" and photos are available at http://www.marapharm.com.

"The plants become 'moms' and cuttings are taken which become production plants. There are several thousand resultant cuttings from a mom over the lifetime of the plant. Marapharm's plants will be transported to larger buildings on site once construction is completed and will produce up to 4 harvests per year. The average wholesale prices in Las Vegas for cannabis are $2800 per pound. One plant in the Marapharm facility will yield up to $175 based on current market conditions. Cannabis sales are predicted to hit $30 billion in the United States by 2021 and Marapharm is positioned to be an industry leader in Las Vegas!" Linda Sampson, Marapharm CEO.

Construction of Marapharm's buildings in Las Vegas is progressing and they have begun the genetic selection process. Marapharm's commitment to excellence begins with selecting the highest quality plant genetics.  

Varieties have been selected that are well known in the cannabis culture for their award winning history and legendary names. These genetics are sourced from the best breeders in the industry and 41 potential mothers have been germinated from legendary cannabis companies such as DNA Genetics, Barney's Farm, Elemental Seeds and Rare Dankness. The final variety selection will be based on similar criteria used by High Times to select Cannabis Cup winning strains. Marapharm will use test results, visual appeal, smell, and alignment with internal cultivation protocols. Strains include award winners such as Kosher Kush, White Widow and Blue Cheese.

ABOUT MARAPHARM VENTURES INC. 

http://www.marapharm.com

Marapharm is a publicly traded company primarily investing in the medical and recreational cannabis space, with corporate operations based in British Columbia, Canada. Since 2016 they have rapidly expanded their footprint to include production locations in the key North American states of Washington, Nevada, and California. They actively seek expansion opportunities worldwide. 

FOR FURTHER INFORMATION:  

http://www.marapharm.com or Linda Sampson, CEO 778-583-4476 email [email protected]  

SOCIAL MEDIA: 

Facebook:  http://www.facebook.com/marapharm

Twitter:  http://www.twitter.com/marapharm  

STOCK EXCHANGES: 

Marapharm trades in Canada, ticker symbol MDM on the CSE, in the United States, ticker symbol MRPHF on the OTCQB, and in Europe, ticker symbol 2Mo on the FSE. Marapharm also trades on other recognized platforms in Europe including Stuttgart, Tradegate, L & S, Quotnx, Dusseldorf, Munich, and Berlin.

Neither the CSE, the FSE nor the OTCQB® has approved nor disapproved the contents of this press release. Neither the CSE, the FSE nor the OTCQB® accepts responsibility for the adequacy or accuracy of this release.

FORWARD - LOOKING STATEMENTS: 

Certain statements contained in this news release constitute forward looking statements. The use of any of the words "anticipate", "continue", "estimate", "expect", 'may", "will", "project", "should", 'believe", and similar expressions are intended to identify forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results or events to differ materially from those anticipated in such forward-looking statements are based on reasonable assumption but no assurance can be given that these expectations will prove to be correct and the forward-looking statements included in this news release should not be unduly relied upon.

FOR FURTHER INFORMATION:  

http://www.marapharm.com or Linda Sampson, CEO +1-778-583-4476 email [email protected]  


SOURCE Marapharm Ventures Inc.


These press releases may also interest you

at 22:00
The Global Health Innovative Technology (GHIT) Fund announced today a total investment of approximately JPY 1.64 billion (USD 10.8 million1) in four projects for the development of new drugs for malaria and neglected tropical diseases (NTDs).2  The...

at 21:00
Renova Therapeutics, a biotechnology company developing gene therapy-based treatments for cardiovascular and metabolic diseases, announced today that it has focused its development and commercialization efforts for its RT-100 and RT-200 gene...

at 20:05
Organovo Holdings, Inc. ("Organovo" or the "Company"), a clinical stage biotechnology company focused on developing novel treatment approaches based on demonstration of clinical promise in three-dimensional (3D) human tissues, today announced the...

at 20:00
Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology...

at 19:30
NCPDP announced today highlights from its 2024 Annual Technology & Business Conference, Innovation Starts Here. "NCPDP's standards and guidance are inherently innovative, and the work we continue to do will expand interoperability to support the...

at 19:25
Edwards Lifesciences today announced the European launch of the SAPIEN 3 Ultra RESILIA valve, the only transcatheter aortic heart valve to incorporate the company's breakthrough RESILIA tissue technology, designed to extend the valve's durability.*...



News published on and distributed by: